

https://www.uspharmacist.com/article/inappropriate-use-of-skeletal-muscle-relaxants-in-geri atric-patients

Drug Category	Mechanism of Action	Condition Treated	Disease States
Antispasmodics	Block nerves from signaling brain	Spasms secondary to peripheral musculoskeletal conditions	Injury, trauma
Antispastics/ spasmolytics	Block nerve signaling from spinal cord; act directly on skeletal muscle to relax spasm	Spasticity secondary to upper motor neuron lesions	Multiple sclerosis, spinal cord injury, stroke, cerebral palsy, infection



2
Ð
p
a
_

A Summary of Available Skeletal Muscle Relaxants **On Beers** Considerations Usual Oral in Geriatric Criteria Approved Agent Indications Adult Dosage List Patients **Clinical Pearls** Duration Antispasmodics Carisoprodol Acute 250 mg-350 mg Yes Efficacy and safety If used long-term, must 2-3 wk musculoskeletal tid + hs^a not established in taper off owing to risk of patients aged >65 y withdrawal effect pain Chlorzoxazone Initial: 250 mg tid; Yes Decrease dose as Rare but serious No Acute musculoskeletal max: 500 mg gid symptoms improve hepatotoxicity duration pain given Cyclobenzaprine Muscle spasm 5 mg-10 mg tid Yes Extended-release Potential for serotonin 2-3 wk (immediateformulation not syndrome; strong anticholinergic release) recommended: consider decreased properties frequency Metaxalone Acute 800 mg tid or gida Yes Caution in patients Potential for serotonin No musculoskeletal with hepatic syndrome, strong antiduration pain impairment cholinergic properties given Methocarbamol Acute Initial: 1,500 mg qid Yes Start at lower dose Mechanism of action Chronic for 2-3 days, then musculoskeletal and titrate to toleris due to sedative use pain; tetanus decrease dosage to ance in geriatric properties; no direct 4 g-4.5 g/day divided patients and those effect on muscles into 3-6 dosesª with hepatic or renal impairment Orphenadrine 100 mg bid Yes Contraindicated Acute Strong anticholinergic No musculoskeletal in patients with properties duration glaucoma given pain Antispastics Baclofen Spasticity Initial: 5 mg tid for No Little/no evidence Potential for large 1-2 mo resulting from number of CNS and ≥3 days, then titrate for use in chronic MS (flexor up by 5 mg q3d; cardiovascular side lower back pain spasms) or max: 80 mg effects spinal cord injuries and diseases Dantrolene Chronic Initial: 25 mg qd for No Drowsiness Black box warning 45 days, spasticity 7 days, then 25 mg tid may persist for hepatotoxicity if no titrated to effect by for 48 h benefit increasing dose q7d, post dose seen not frequency; max: 400 mg (100 mg qid) Antispasmodic and Antispastic With Geriatric Dosage

Diazepam	Muscle spasm caused by local pathology; spasticity	2 mg-10 mg po tid or qid Geriatric dosage: 2 mg-2.5 mg qd or bid; increase as tolerated	Yes	Increased risk of death with use	Associated with falls and traumatic injuries	No duration given
Tizanidine	Spasticity	2 mg-12 mg qd to tid Geriatric dosage: 2 mg qd to qid; titrate as needed; max: 36 mg	Yes ^b	Calculate creatinine clearance prior to dosing	Reserve treatment for time of day when control of spasticity is most important	No duration given

^a A dose decrease is recommended in renal impairment. ^b Tizanidine appears on the Beers Criteria list secondary to its potential to reduce urinary flow in men. There is no listed concern for sedation or potential fall risk.

CNS: central nervous system; max: maximum; MS: multiple sclerosis. Source: References 3, 8, 9.

Indication	Skeletal Muscle Relaxants	Possible Alternatives
Acute low back pain	Short-term cyclobenzaprine, carisoprodol, metaxalone, methocarbamol	Physical therapy, ibuprofen (if no heart failure, hypertension, other considerations)
Chronic low back pain	Should not be used	Physical therapy, NSAIDs, tramadol, opioids ^a
Spasticity	Baclofen, tizanidine, dantrolene scheduled	Physical therapy; baclofen, tizanidine, dantrolene as needed

NSAID: nonsteroidal anti-inflammatory drug. Source: References 19, 21.